{
  "meta": {
    "title": "Bone_Mineral_And_Metabolic_Disorders",
    "url": "https://brainandscalpel.vercel.app/bone-mineral-and-metabolic-disorders-a89ef84c.html",
    "scrapedAt": "2025-11-30T08:49:00.777Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Alkaptonuria</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Homocystinuria</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenylketonuria</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Ornithine Transcarbamylase Deficiency</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 3-year-old child presents with developmental delay, seizures, and hypopigmentation of hair and skin. The urine has a characteristic \"musty\" odor. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295327",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295327,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\n<li><strong>Phenylketonuria (PKU)</strong> is caused by a <strong>deficiency in the enzyme phenylalanine hydroxylase</strong>, which leads to the accumulation of <strong>phenylalanine</strong> in the blood.\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501084747f28f-7a46-41f4-9b73-671947e9de75.jpg\"></li>\n<li>Elevated phenylalanine levels result in <strong>neurotoxicity</strong>, manifesting as <strong>developmental delay, intellectual disability</strong>, and <strong>seizures</strong>.</li>\n<li><strong>Hypopigmentation</strong> occurs because phenylalanine is a precursor to melanin, and its buildup inhibits melanin production, leading to <strong>fair skin, light hair</strong>, and light eye color.</li>\n<li>A distinctive <strong>\"musty\" odor</strong> in urine is caused by the breakdown products of phenylalanine.</li>\n<li>Early detection through <strong>newborn screening</strong> is crucial for preventing the severe neurological consequences of untreated PKU.</li>\n</ol>\n<p><strong>Incorrect Options:</strong></p>\n<ul>\n<li><strong>Alkaptonuria</strong>: Associated with darkening of urine on standing, ochronosis, and joint degeneration but not with developmental delay or seizures.</li>\n<li><strong>Homocystinuria</strong>: Features include marfanoid habitus, lens dislocation, thromboembolic events, and intellectual disability, but no musty odor in urine.</li>\n<li><strong>Ornithine Transcarbamylase Deficiency</strong>: A urea cycle disorder with hyperammonemia, presenting with vomiting, lethargy, and coma, but not with hypopigmentation or musty odor.</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>Phenylketonuria</strong> is an <strong>autosomal recessive disorder</strong>.</li>\n<li>Newborn screening allows for early dietary management to prevent intellectual disability.</li>\n<li><strong>Dietary restriction of phenylalanine</strong> is the mainstay of treatment.</li>\n</ul>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">70 mg orally once weekly</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">35 mg orally once weekly</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">5 mg IV annually</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">150 mg orally once monthly</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old woman with osteoporosis is prescribed zoledronic acid. What is the typical dosing schedule for this medication?</span></p>",
      "unique_key": "DT1295328",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295328,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Zoledronic acid</strong> is a <strong>potent bisphosphonate</strong> that works by inhibiting osteoclast-mediated bone resorption.</li>\r\n<li>It is administered <strong>intravenously (IV) once a year</strong> at a dose of <strong>5 mg</strong> to treat osteoporosis in postmenopausal women.</li>\r\n<li>Zoledronic acid has the advantage of <strong>once-yearly dosing</strong>, improving adherence compared to oral bisphosphonates that require more frequent administration.</li>\r\n<li>Studies have shown that zoledronic acid reduces the risk of both <strong>vertebral and non-vertebral fractures</strong>.</li>\r\n<li>This medication is particularly beneficial for patients who have difficulty adhering to more frequent oral bisphosphonate regimens.</li>\r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Option A (70 mg orally once weekly)</strong>: Refers to the dosing schedule for <strong>alendronate</strong>, another bisphosphonate.</li>\r\n<li><strong>Option B (35 mg orally once weekly)</strong>: Refers to <strong>risedronate</strong>, an oral bisphosphonate.</li>\r\n<li><strong>Option D (150 mg orally once monthly)</strong>: Describes the dosing of <strong>ibandronate</strong>, another bisphosphonate.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Zoledronic acid is an effective <strong>annual IV bisphosphonate</strong> used in the treatment of osteoporosis.</li>\r\n<li>It is convenient for patients due to its <strong>once-yearly dosing</strong> and effectively reduces fracture risk.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Runx2</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">NF-&kappa;B</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">PPAR&gamma;</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">STAT3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which transcription factor is essential for osteoblast differentiation and regulation of bone matrix proteins?</span></p>",
      "unique_key": "DT1295330",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295330,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Runx2</strong> (Runt-related transcription factor 2) is the <strong>master regulator</strong> for osteoblast differentiation.</li>\r\n<li>It plays a crucial role in the <strong>formation of bone matrix proteins</strong>, including <strong>type I collagen</strong> and <strong>osteocalcin</strong>, which are essential components for bone structure.</li>\r\n<li><strong>Runx2</strong> directs the commitment of mesenchymal stem cells to the osteoblast lineage, promoting the development and activity of osteoblasts.</li>\r\n<li>Mutations or dysfunctions in the <strong>Runx2 gene</strong> can result in <strong>skeletal deformities</strong>, such as cleidocranial dysplasia, a condition characterized by defective bone formation.</li>\r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>NF-&kappa;B</strong>: Primarily involved in immune response regulation and inflammation but not specifically in osteoblast differentiation.</li>\r\n<li><strong>PPAR&gamma;</strong>: A key transcription factor for <strong>adipocyte differentiation</strong>, not for bone formation.</li>\r\n<li><strong>STAT3</strong>: Plays a role in cell growth and immune responses, but not specifically in osteoblast differentiation.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Runx2</strong> is essential for <strong>osteoblast differentiation</strong> and the production of <strong>bone matrix proteins</strong>.</li>\r\n<li><strong>Mutations in Runx2</strong> can cause skeletal disorders like <strong>cleidocranial dysplasia</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduces hip fracture risk</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases the risk of breast cancer</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduces vertebral fracture risk</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases bone turnover</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Raloxifene is an FDA-approved treatment for osteoporosis. Which of the following is a benefit of raloxifene?</span></p>",
      "unique_key": "DT1295331",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295331,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Raloxifene</strong> is a <strong>Selective Estrogen Receptor Modulator (SERM)</strong> that mimics estrogen's positive effects on bone density without the risks associated with estrogen therapy.</li>\r\n<li>It has been proven to <strong>reduce the risk of vertebral fractures</strong> in postmenopausal women with osteoporosis but has <strong>no significant effect on reducing hip fractures</strong>.</li>\r\n<li>Raloxifene also has the added benefit of <strong>reducing the risk of invasive breast cancer</strong> by acting as an estrogen antagonist in breast tissue.</li>\r\n<li><strong>Bone turnover</strong> is decreased with raloxifene, leading to enhanced bone density without increasing fracture risk elsewhere.</li>\r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Option A (Reduces hip fracture risk)</strong>: Raloxifene is not effective in reducing hip fracture risk.</li>\r\n<li><strong>Option B (Increases the risk of breast cancer)</strong>: Raloxifene actually <strong>reduces</strong> the risk of invasive breast cancer.</li>\r\n<li><strong>Option D (Increases bone turnover)</strong>: Raloxifene <strong>decreases</strong> bone turnover, leading to improved bone density.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Raloxifene</strong> reduces the risk of <strong>vertebral fractures</strong> but not hip fractures.</li>\r\n<li>It is also beneficial in <strong>reducing the risk of invasive breast cancer</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary hyperparathyroidism</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial hypocalciuric hypercalcemia</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypercalcemia of malignancy</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin D intoxication</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old man presents with nephrolithiasis. His serum calcium is 12.0 mg/dL, and PTH levels are elevated. He has a history of hypertension and has been on thiazide diuretics for several years. Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295333",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295333,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Primary hyperparathyroidism</strong> is characterized by <strong>elevated serum calcium</strong> and <strong>elevated parathyroid hormone (PTH)</strong> levels.</li>\r\n<li>Patients often present with <strong>nephrolithiasis</strong> (kidney stones), caused by hypercalcemia, which leads to increased calcium in the urine.</li>\r\n<li><strong>Thiazide diuretics</strong> can reduce calcium excretion, potentially <strong>unmasking hypercalcemia</strong> in patients who have underlying hyperparathyroidism.</li>\r\n<li>In this case, discontinuing the thiazide diuretic would typically not resolve the hypercalcemia, pointing toward <strong>primary hyperparathyroidism</strong> as the cause.</li>\r\n<li>Other causes of hypercalcemia, such as malignancy or vitamin D intoxication, usually show <strong>suppressed PTH levels</strong>.</li>\r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Familial hypocalciuric hypercalcemia</strong>: Usually presents with <strong>mild hypercalcemia</strong>, low urinary calcium excretion, and normal or mildly elevated PTH, but nephrolithiasis is uncommon.</li>\r\n<li><strong>Hypercalcemia of malignancy</strong>: PTH levels are typically <strong>low</strong> due to PTH-independent hypercalcemia.</li>\r\n<li><strong>Vitamin D intoxication</strong>: Causes hypercalcemia due to excess calcium absorption but results in <strong>low PTH levels</strong>.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Primary hyperparathyroidism</strong> is the most common cause of <strong>elevated calcium and PTH levels</strong> in adults, often leading to nephrolithiasis.</li>\r\n<li>Thiazide diuretics can <strong>reduce renal calcium excretion</strong>, and their discontinuation may not fully resolve hypercalcemia if <strong>primary hyperparathyroidism</strong> is the underlying cause.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypophosphatemia</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperphosphatemia</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Elevated parathyroid hormone</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Low 1,25-dihydroxyvitamin D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following laboratory findings is commonly associated with tumoral calcinosis?</span></p>",
      "unique_key": "DT1295334",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295334,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Tumoral calcinosis</strong> is a rare genetic disorder primarily caused by mutations affecting <strong>FGF23 signaling</strong>, which leads to <strong>hyperphosphatemia</strong>.</li>\r\n<li><strong>FGF23</strong> normally regulates phosphate homeostasis by decreasing renal phosphate reabsorption. In tumoral calcinosis, mutations cause reduced FGF23 activity or resistance, leading to excessive <strong>phosphate reabsorption</strong> in the kidneys.</li>\r\n<li>This results in <strong>elevated serum phosphate levels</strong> and the deposition of calcium phosphate complexes in soft tissues, typically near major joints.</li>\r\n<li>The calcific masses are usually <strong>painless</strong> and grow at variable rates, sometimes becoming large and bulky, but they can compress surrounding structures or ulcerate.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Hyperphosphatemia</strong> is a hallmark finding in <strong>tumoral calcinosis</strong>, and it results from defective <strong>FGF23 function</strong>, leading to increased phosphate reabsorption in the kidneys.</li>\r\n<li>This disorder is characterized by <strong>calcium phosphate deposits</strong> in soft tissues, primarily around joints.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Nutritional rickets</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin D-dependent rickets</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypophosphatemic rickets</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Pseudohypoparathyroidism</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 7-year-old boy presents with short stature, bowing of the legs, and dental abscesses. His laboratory results show normal calcium, low phosphorus, and elevated alkaline phosphatase. Genetic testing reveals a mutation in the PHEX gene. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295336",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295336,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Hypophosphatemic rickets</strong> is often caused by <strong>X-linked dominant mutations in the PHEX gene</strong>, leading to <strong>renal phosphate wasting</strong>.</li>\r\n<li>This disorder is characterized by <strong>low serum phosphate</strong> levels, <strong>normal serum calcium</strong>, and <strong>elevated alkaline phosphatase</strong> due to defective bone mineralization.</li>\r\n<li>Clinical features include <strong>short stature</strong>, <strong>bowing of the legs</strong>, and <strong>dental issues</strong> such as abscesses, which occur because of defective dentin formation.</li>\r\n<li>Unlike nutritional rickets, <strong>hypophosphatemic rickets</strong> does not respond well to vitamin D supplementation alone. Treatment typically involves <strong>phosphate supplements</strong> and <strong>active forms of vitamin D (calcitriol)</strong> to enhance bone mineralization.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Hypophosphatemic rickets</strong> is a genetic disorder that leads to <strong>phosphate wasting</strong> and defective bone mineralization, presenting with classic rickets symptoms like leg bowing.</li>\r\n<li><strong>PHEX gene mutations</strong> are the most common cause, and treatment requires <strong>phosphate supplements and active vitamin D</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteosarcoma</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">High-output cardiac failure</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Hearing loss</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypocalcemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a complication of Paget's disease of bone?</span></p>",
      "unique_key": "DT1295337",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295337,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Paget's disease of bone</strong> involves disorganized bone remodeling, leading to a variety of complications such as <strong>osteosarcoma</strong> (rare but serious), <strong>high-output cardiac failure</strong> (in extensive disease), and <strong>hearing loss</strong> (due to skull involvement).</li>\r\n<li><strong>Hypocalcemia</strong>, however, is <strong>not typically associated with Paget's disease</strong>. In fact, calcium levels are usually normal, and the disease primarily affects bone turnover and architecture rather than calcium metabolism directly.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Paget's disease can lead to complications including <strong>osteosarcoma</strong>, <strong>hearing loss</strong>, and <strong>high-output cardiac failure</strong>, but it does not typically cause <strong>hypocalcemia</strong>.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary hyperparathyroidism</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial hypocalciuric hypercalcemia</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypercalcemia of malignancy</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin D intoxication</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old man presents with nephrolithiasis. His serum calcium is 12.0 mg/dL, and PTH levels are elevated. He has a history of hypertension and has been on thiazide diuretics for several years. Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295338",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295338,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Primary hyperparathyroidism (PHPT)</strong> is the most common cause of <strong>hypercalcemia</strong> in outpatients and is characterized by <strong>elevated parathyroid hormone (PTH)</strong> along with hypercalcemia.</li>\r\n<li><strong>Nephrolithiasis (kidney stones)</strong> is a common complication of <strong>primary hyperparathyroidism</strong>, as excess calcium is filtered and excreted through the kidneys, increasing the risk of stone formation.</li>\r\n<li><strong>Thiazide diuretics</strong> reduce renal calcium excretion, which can sometimes <strong>unmask</strong> underlying hypercalcemia in patients with primary hyperparathyroidism. Discontinuing the thiazide typically will not resolve the hypercalcemia in these cases.</li>\r\n<li>Other causes of hypercalcemia, such as malignancy, are usually associated with <strong>low or suppressed PTH levels</strong>.</li>\r\n<li>Elevated <strong>PTH</strong> in the context of hypercalcemia is diagnostic of <strong>primary hyperparathyroidism</strong> unless familial hypocalciuric hypercalcemia (FHH) is suspected, which is rarer and typically presents with a benign course and lower urinary calcium excretion.</li>\r\n</ol>\r\n<p><strong>Key Takeaways</strong><strong>:</strong></p>\r\n<ul>\r\n<li><strong>Primary hyperparathyroidism</strong> is the leading cause of hypercalcemia and is commonly associated with <strong>nephrolithiasis</strong>.</li>\r\n<li>Thiazide diuretics can increase serum calcium, but underlying hyperparathyroidism remains the primary issue if discontinuation does not resolve hypercalcemia.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">1 &rarr; C , 2 &rarr; A, 3 &rarr; B, 4 &rarr; D</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">1 &rarr; A , 2 &rarr; B, 3 &rarr; C, 4 &rarr; D</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">1 &rarr; D , 2 &rarr; A, 3 &rarr; C, 4 &rarr; D</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">1 &rarr; A , 2 &rarr; C, 3 &rarr; B, 4 &rarr; D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the Following: Metabolic Disorders<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501081a9d5ecd-58dd-4841-b714-122a4f001beb.jpg\"></span></p>",
      "unique_key": "DT1295341",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295341,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>1 &rarr; C: <strong>Phenylketonuria (PKU)</strong> is caused by a deficiency of <strong>phenylalanine hydroxylase</strong>, leading to the accumulation of phenylalanine, which causes developmental delay and intellectual disability if untreated.<br /> 2 &rarr; A: <strong>Homocystinuria</strong> is caused by a deficiency in <strong>cystathionine &beta;-synthase</strong>, resulting in elevated homocysteine levels and associated with marfanoid features and thromboembolic events.<br /> 3 &rarr; B: <strong>Alkaptonuria</strong> results from a deficiency in <strong>homogentisic acid oxidase</strong>, leading to the accumulation of homogentisic acid, which causes darkening of urine and ochronosis.<br /> 4 &rarr; D: <strong>Methylmalonic acidemia</strong> is caused by a deficiency in <strong>methylmalonyl-CoA mutase</strong>, leading to the accumulation of methylmalonic acid and presenting with metabolic acidosis and developmental delays.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>These metabolic disorders result from enzyme deficiencies in key metabolic pathways.</li>\r\n<li><strong>PKU</strong> is screened for in newborns to prevent the severe consequences of untreated disease.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Both Assertion and Reason are true, and Reason is the correct explanation of Assertion</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Both Assertion and Reason are true, but Reason is not the correct explanation of Assertion</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Assertion is true, but Reason is false</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Both Assertion and Reason are false</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Assertion: Zoledronic acid is the most potent bisphosphonate for osteoporosis treatment.<br>Reason: Zoledronic acid is administered orally and taken once monthly.</span></p>",
      "unique_key": "DT1295343",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295343,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Zoledronic acid</strong> is indeed the most potent bisphosphonate available for the treatment of osteoporosis, due to its strong inhibition of osteoclast activity and long-lasting effects.</li>\r\n<li>However, <strong>zoledronic acid is not taken orally</strong>. It is administered <strong>intravenously (IV) once a year</strong>, making it highly convenient for patients who have difficulties with the more frequent oral dosing schedules of other bisphosphonates like alendronate.</li>\r\n<li>Oral bisphosphonates such as <strong>alendronate</strong> or <strong>risedronate</strong> are taken once weekly or monthly, but zoledronic acid is strictly intravenous.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Zoledronic acid</strong> is a powerful, long-acting bisphosphonate administered <strong>IV once annually</strong>, providing a convenient treatment option for osteoporosis with less frequent dosing compared to oral agents.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoclasts are derived from hematopoietic precursors</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoblasts secrete alkaline phosphatase, essential for bone mineralization</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteocytes act as mechanosensors within the bone</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcitonin increases osteoclast activity, promoting bone resorption</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the incorrect statement regarding bone remodeling:</span></p>",
      "unique_key": "DT1295344",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295344,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Osteoclasts</strong> are derived from <strong>hematopoietic stem cells</strong>, specifically from the monocyte/macrophage lineage, and are responsible for bone resorption.</li>\r\n<li><strong>Osteoblasts</strong> are responsible for bone formation and secrete enzymes like <strong>alkaline phosphatase</strong>, which is critical for bone mineralization.</li>\r\n<li><strong>Osteocytes</strong>, which are former osteoblasts embedded within the bone matrix, act as <strong>mechanosensors</strong>, helping to regulate bone remodeling in response to mechanical stress.</li>\r\n<li>The incorrect statement is about <strong>calcitonin</strong>. Rather than <strong>increasing osteoclast activity</strong>, calcitonin actually <strong>inhibits osteoclasts</strong>, thereby <strong>reducing bone resorption</strong>. Calcitonin acts to lower blood calcium levels, opposing the action of parathyroid hormone (PTH).</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Calcitonin</strong> is used in the treatment of conditions like <strong>Paget's disease</strong> and <strong>hypercalcemia</strong> due to its ability to inhibit osteoclast activity.</li>\r\n<li>Bone remodeling involves a delicate balance between the activities of osteoclasts (resorption) and osteoblasts (formation).</li>\r\n</ul>\r\n ",
      "correct_choice_id": 114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoporosis</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteomalacia</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Paget's disease of bone</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteopetrosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old man presents with bone pain and hearing loss. Physical exam shows frontal bossing and bowing of the legs. Laboratory studies reveal elevated alkaline phosphatase levels. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295345",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295345,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Paget's disease of bone</strong> is a chronic disorder characterized by <strong>disorganized bone remodeling</strong>, with an excessive breakdown of bone by osteoclasts followed by an abnormal bone formation by osteoblasts.</li>\r\n<li>Clinical features include <strong>bone pain</strong>, <strong>hearing loss</strong> (due to involvement of the bones in the skull), and skeletal deformities such as <strong>frontal bossing</strong> (prominent forehead) and <strong>bowing of the legs</strong>.</li>\r\n<li>Laboratory findings typically show <strong>elevated alkaline phosphatase (ALP)</strong>, which reflects increased bone turnover, a hallmark of Paget';s disease.</li>\r\n<li>Paget's disease most commonly affects the <strong>pelvis, skull, spine, and long bones</strong> of the legs.</li>\r\n<li>Treatment usually involves <strong>bisphosphonates</strong>, which help reduce bone turnover and alleviate symptoms.</li>\r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Paget's disease</strong> is characterized by <strong>excessive and disorganized bone remodeling</strong>, leading to structural abnormalities and bone pain.</li>\r\n<li>Elevated <strong>alkaline phosphatase</strong> levels are a key diagnostic marker for increased bone activity in Paget's disease.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteopetrosis</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteogenesis imperfecta</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Paget's disease of bone</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Rickets</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 6-month-old infant presents with failure to thrive, recurrent infections, and hepatosplenomegaly. X-rays reveal diffuse sclerosis of bones with a \"bone within a bone\" appearance. Laboratory results show pancytopenia. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295346",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295346,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Osteopetrosis</strong>, also known as <strong>marble bone disease</strong>, is a rare genetic disorder characterized by <strong>defective osteoclast function</strong> or development, leading to impaired bone resorption. This results in <strong>abnormally dense bones</strong>.</li>\r\n<li>The clinical presentation includes <strong>failure to thrive</strong>, <strong>recurrent infections</strong>, and <strong>hepatosplenomegaly</strong>, which occur due to the replacement of bone marrow by sclerotic bone, leading to <strong>pancytopenia</strong> (reduction of all blood cell types).</li>\r\n<li>X-rays often show the classic <strong>\"bone within a bone\" appearance</strong> or diffuse sclerosis, which is a hallmark of osteopetrosis.</li>\r\n<li>The dense but brittle bones increase the risk of fractures despite their increased bone mass.</li>\r\n<li><strong>Bone marrow transplantation</strong> is a potential treatment, especially in the severe infantile forms, as it can help restore osteoclast function.</li>\r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Osteogenesis imperfecta</strong>: This condition is characterized by brittle bones and frequent fractures, but it is associated with <strong>blue sclera</strong> and does not show the \"bone within a bone\" appearance on X-rays.</li>\r\n<li><strong>Paget's disease of bone</strong>: Usually presents in adults with bone pain, deformities, and elevated alkaline phosphatase, but it does not present in infancy with pancytopenia.</li>\r\n<li><strong>Rickets</strong>: This is a condition caused by vitamin D deficiency, leading to bone deformities, but it shows <strong>widened epiphyseal plates</strong> and <strong>bowing of legs</strong> rather than sclerotic bones.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Osteopetrosis</strong> results in <strong>abnormally dense but brittle bones</strong>, leading to complications like <strong>pancytopenia</strong>, recurrent infections, and bone fractures.</li>\r\n<li><strong>Bone marrow transplantation</strong> can be a curative treatment option in severe cases.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Achondroplasia</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">McCune-Albright syndrome</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Fibrous dysplasia</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteogenesis imperfecta</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 15-year-old girl presents with unilateral cafe-au-lait spots, recurrent fractures, and xray in her legs shows this. She also has a history of early puberty. What is the most likely diagnosis?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010820f0c6c7-157a-42a9-9674-e2c34fe771f1.jpg\"></span></p>",
      "unique_key": "DT1295347",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295347,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>McCune-Albright syndrome (MAS)</strong> is a genetic disorder characterized by a <strong>triad of findings</strong>: <strong>polyostotic fibrous dysplasia</strong> (abnormal fibrous tissue replacing normal bone), <strong>cafe-au-lait spots</strong>, and <strong>endocrine abnormalities</strong> such as <strong>precocious puberty</strong> or hyperthyroidism.</li>\r\n<li><strong>Fibrous dysplasia</strong>, a component of MAS, leads to <strong>irregular bone growth</strong> and <strong>recurrent fractures</strong>, commonly affecting the long bones, ribs, and skull.</li>\r\n<li><strong>Cafe-au-lait spots</strong> are typically <strong>unilateral</strong> and have an irregular 'coast of Maine' border, which is a distinguishing feature.</li>\r\n<li><strong>Early puberty</strong> is a hallmark of MAS due to its effects on endocrine function.</li>\r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Achondroplasia</strong>: This condition results in <strong>short stature</strong> due to defects in cartilage formation, but does not present with cafe-au-lait spots or precocious puberty.</li>\r\n<li><strong>Fibrous dysplasia</strong>: While fibrous dysplasia is a key feature of MAS, it <strong>alone</strong> does not explain the <strong>endocrine abnormalities</strong> or cafe-au-lait spots seen in MAS.</li>\r\n<li><strong>Osteogenesis imperfecta</strong>: This condition is characterized by <strong>brittle bones</strong> and frequent fractures but is not associated with cafe-au-lait spots or early puberty.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>McCune-Albright syndrome</strong> includes a combination of <strong>polyostotic fibrous dysplasia</strong>, <strong>cafe-au-lait spots</strong>, and <strong>precocious puberty</strong> or other endocrine dysfunctions.</li>\r\n<li><strong>Fibrous dysplasia</strong> alone lacks the systemic endocrine features and skin manifestations seen in MAS.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Acromegaly</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Secondary hypertrophic osteoarthropathy</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Pachydermoperiostosis</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Rheumatoid arthritis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 17-year-old male presents with clubbing of the digits, hyperhidrosis, and thickened skin on the face and forehead. He has a paw-like appearance of the hands and feet. Radiographs reveal periosteal new bone formation. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295348",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295348,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Pachydermoperiostosis, or <strong>primary hypertrophic osteoarthropathy</strong>, is a rare, autosomal dominant disorder characterized by <strong>periosteal new bone formation</strong>, <strong>clubbing</strong>, and <strong>thickening of the skin</strong> (especially on the face and forehead). The <strong>paw-like appearance</strong> of the hands and feet can mimic acromegaly, but the absence of elevated growth hormone levels distinguishes it.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Primary hypertrophic osteoarthropathy</strong> involves clubbing, skin thickening, and periosteal bone formation.</li>\r\n<li>Differentiation from <strong>secondary hypertrophic osteopathy</strong> (due to pulmonary disease) can be made by radiographic findings showing an <strong>irregular periosteal surface</strong> in primary disease.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}